Journal Watch · Frontiers in Immunology · 2026

AI-driven radiomics and radiogenomics: supporting the assessment and differentiation of pseudoprogression in cellular immunotherapy for glioblastoma.

The above ways can reduce the bias induced by PsP and improve differentiation between pseudoprogression and true progression to facilitate prompt treatment for most people.

Han Y, Li W, Jin Y et al.Frontiers in Immunology3 min readPharma relevance 95/100

DOI: 10.3389/fimmu.2026.1920605PMID: 42751249Study type: cohort / observational clinical study

TL;DR

The above ways can reduce the bias induced by PsP and improve differentiation between pseudoprogression and true progression to facilitate prompt treatment for most people.

Key findings

  • Clinical translation still faces numerous limitations such as inconsistent research protocols, small study cohorts, insufficient external validation, inadequate model interpretability and inconsistent reference standards.
  • In the future, many research groups will conduct multi-centre validation, standardize workflows, open-source reporting and release clinically interpretable models.
  • The above ways can reduce the bias induced by PsP and improve differentiation between pseudoprogression and true progression to facilitate prompt treatment for most people.

What they did

Artificial Intelligence (AI)-based radiomics and radiogenomics aid in the characterisation of GBM. Several Magnetic Resonance Imaging (MRI) sequences are used to obtain quantitative data, such as the conventional T1-weighted images, diffusion-weighted images, perfusion-weighted images and others, to acquire information on cell density, blood vessel distribution, immune cell concentration, molecular modifications and the effect of therapy. Combine imaging characteristics with liquid biopsy, genomic data and patient health records to enhance the accuracy of diagnosis and discover high-sensitivity surrogate markers for immune checkpoint inhibitor and CAR-T cell therapy clinical trials.

Full abstract (original)

Background: Glioblastoma (GBM) is the most aggressive type of primary brain tumour in adults, and after treatment, it is also difficult to know whether a person's health has improved. Pseudoprogression (PsP), particularly following radiotherapy and combination therapy with temozolomide and new immunotherapies, may be falsely identified as true progression (TP) by conventional MRI, thus leading to premature termination of treatment or unnecessary intensification of therapy. Although RANO, iRANO and RANO 2.0 have improved the assessment of response, structural MRI alone is unable to reveal the biological complexity of the tumour microenvironment.

What they did: Artificial Intelligence (AI)-based radiomics and radiogenomics aid in the characterisation of GBM. Several Magnetic Resonance Imaging (MRI) sequences are used to obtain quantitative data, such as the conventional T1-weighted images, diffusion-weighted images, perfusion-weighted images and others, to acquire information on cell density, blood vessel distribution, immune cell concentration, molecular modifications and the effect of therapy. Combine imaging characteristics with liquid biopsy, genomic data and patient health records to enhance the accuracy of diagnosis and discover high-sensitivity surrogate markers for immune checkpoint inhibitor and CAR-T cell therapy clinical trials.

Results & conclusions: Clinical translation still faces numerous limitations such as inconsistent research protocols, small study cohorts, insufficient external validation, inadequate model interpretability and inconsistent reference standards. In the future, many research groups will conduct multi-centre validation, standardize workflows, open-source reporting and release clinically interpretable models. The above ways can reduce the bias induced by PsP and improve differentiation between pseudoprogression and true progression to facilitate prompt treatment for most people.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1920605 · PubMed 42751249.

Why it matters for pharma & biotech

  • Directly relevant to teams in cell therapy (CAR-T / engineered cells), targeted oncology / immuno-oncology, small-molecule drug discovery, AI in drug discovery / diagnostics — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: cell therapy (CAR-T / engineered cells) · targeted oncology / immuno-oncology · small-molecule drug discovery · AI in drug discovery / diagnostics

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

The above ways can reduce the bias induced by PsP and improve differentiation between pseudoprogression and true progression to facilitate prompt treatment for most people.

What type of study is this?

It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Artificial Intelligence (AI)-based radiomics and radiogenomics aid in the characterisation of GBM.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1920605. PubMed ID: 42751249. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Han Y, Li W, Jin Y et al.. AI-driven radiomics and radiogenomics: supporting the assessment and differentiation of pseudoprogression in cellular immunotherapy for glioblastoma.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1920605.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/ai-driven-radiomics-and-radiogenomics-supporting-the-assessment-and-diff-920605/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides